A 74-Year-Old-Man with Metastatic Prostate Cancer - Episode 7

The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.